Brief: Biofrontera Inc - Data Now Being Analyzed, Interim Results Expected November 2024
14/10/2024 15:48
Oct 14 (Reuters) - Biofrontera Inc BFRI.O :
* BIOFRONTERA INC. ANNOUNCES DATABASE LOCK OF PHASE 3 STUDY
OF
AMELUZ®-PHOTODYNAMIC THERAPY (PDT) IN THE TREATMENT OF
SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
* BIOFRONTERA INC - DATA NOW BEING ANALYZED, INTERIM RESULTS
EXPECTED NOVEMBER 2024
* BIOFRONTERA INC - LAST PATIENT FOLLOW-UP EXPECTED BY DEC,
FDA
SUBMISSION TARGETED FOR Q1 2025
Source text for Eikon: ID:nGNXch2D2B
Further company coverage: BFRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales